Literature DB >> 27520379

Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses.

Edwin Chiu Yuen Chow1,2, Arjang Talattof1,2, Eleftheria Tsakalozou1,2, Jianghong Fan1,2, Liang Zhao1,2, Xinyuan Zhang3,4.   

Abstract

Drug solubility, effective permeability, and intestinal metabolism and transport are parameters that govern intestinal bioavailability and oral absorption. However, excipients may affect the systemic bioavailability of a drug by altering these parameters. Thus, parameter sensitivity analyses using physiologically based pharmacokinetic (PBPK) models were performed to examine the potential impact of excipients on oral drug absorption of different Biopharmaceutics Classification System (BCS) class drugs. The simulation results showed that changes in solubility had minimal impact on Cmax and AUC0-t of investigated BCS class 1 and 3 drugs. Changes in passive permeability altered Cmax more than AUC0-t for BCS class 1 drugs but were variable and drug-specific across different BCS class 2 and 3 drugs. Depending on the drug compounds for BCS class 1 and 2 drugs, changes in intestinal metabolic activity altered Cmax and AUC0-t. Reducing or increasing influx and efflux transporter activity might likely affect Cmax and AUC0-t of BCS class 2 and 3 drugs, but the magnitude may be drug dependent. Changes in passive permeability and/or transporter activity for BCS class 2 and 3 drugs might also have a significant impact on fraction absorbed and systemic bioavailability while changes in intestinal metabolic activity may have an impact on gut and systemic bioavailability. Overall, we demonstrate that PBPK modeling can be used routinely to examine sensitivity of bioavailability based on physiochemical and physiological factors and subsequently assess whether biowaiver requirements need consideration of excipient effects for immediate release oral solid dosage forms.

Keywords:  Biopharmaceutics Classification System (BCS); PBPK modeling; excipients; gastrointestinal transporters; oral drug absorption

Mesh:

Substances:

Year:  2016        PMID: 27520379     DOI: 10.1208/s12248-016-9964-4

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  48 in total

1.  Effect of chitosan on epithelial permeability and structure.

Authors:  V Dodane; M Amin Khan; J R Merwin
Journal:  Int J Pharm       Date:  1999-05-10       Impact factor: 5.875

2.  Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT).

Authors:  P J Sinko; Y H Lee; V Makhey; G D Leesman; J P Sutyak; H Yu; B Perry; C L Smith; P Hu; E J Wagner; L M Falzone; L T McWhorter; J P Gilligan; W Stern
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

3.  Pharmaceutical excipients influence the function of human uptake transporting proteins.

Authors:  Anett Engel; Stefan Oswald; Werner Siegmund; Markus Keiser
Journal:  Mol Pharm       Date:  2012-08-01       Impact factor: 4.939

4.  Thiopental pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick
Journal:  J Pharm Sci       Date:  1968-08       Impact factor: 3.534

Review 5.  The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.

Authors:  Leslie Z Benet
Journal:  J Pharm Sci       Date:  2012-11-12       Impact factor: 3.534

6.  P-glycoprotein and surfactants: effect on intestinal talinolol absorption.

Authors:  Katrijn Bogman; Yvonne Zysset; Lukas Degen; Gérard Hopfgartner; Heike Gutmann; Jochem Alsenz; Juergen Drewe
Journal:  Clin Pharmacol Ther       Date:  2005-01       Impact factor: 6.875

7.  Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.

Authors:  Meret Martin-Facklam; Jürgen Burhenne; Reinhard Ding; Ruth Fricker; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

8.  Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans.

Authors:  Hong-Jaan Wang; Cheng-Huei Hsiong; Shung-Tai Ho; Min-Jen Lin; Tung-Yuan Shih; Pei-Wei Huang; Oliver Yoa-Pu Hu
Journal:  Pharm Res       Date:  2014-02-14       Impact factor: 4.200

9.  Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes.

Authors:  Yasushi Shono; Hisayo Nishihara; Yasuyuki Matsuda; Shiori Furukawa; Naoki Okada; Takuya Fujita; Akira Yamamoto
Journal:  J Pharm Sci       Date:  2004-04       Impact factor: 3.534

10.  The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin.

Authors:  I A de Lannoy; M Silverman
Journal:  Biochem Biophys Res Commun       Date:  1992-11-30       Impact factor: 3.575

View more
  7 in total

1.  Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products.

Authors:  Zhanglin Ni; Arjang Talattof; Jianghong Fan; Eleftheria Tsakalozou; Satish Sharan; Dajun Sun; Hong Wen; Liang Zhao; Xinyuan Zhang
Journal:  AAPS J       Date:  2017-03-29       Impact factor: 4.009

2.  Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP.

Authors:  Ling Zou; Joshua Pottel; Natalia Khuri; Huy X Ngo; Zhanglin Ni; Eleftheria Tsakalozou; Mark S Warren; Yong Huang; Brian K Shoichet; Kathleen M Giacomini
Journal:  Mol Pharm       Date:  2020-02-10       Impact factor: 4.939

Review 3.  A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development.

Authors:  Marilyn N Martinez; Fang Wu; Balint Sinko; David J Brayden; Michael Grass; Filippos Kesisoglou; Aaron Stewart; Kiyohiko Sugano
Journal:  AAPS J       Date:  2022-05-02       Impact factor: 4.009

4.  Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model.

Authors:  Bart Hens; Arjang Talattof; Paulo Paixão; Marival Bermejo; Yasuhiro Tsume; Raimar Löbenberg; Gordon L Amidon
Journal:  AAPS J       Date:  2018-03-29       Impact factor: 4.009

Review 5.  Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.

Authors:  Mohamad Shebley; Punam Sandhu; Arian Emami Riedmaier; Masoud Jamei; Rangaraj Narayanan; Aarti Patel; Sheila Annie Peters; Venkatesh Pilla Reddy; Ming Zheng; Loeckie de Zwart; Maud Beneton; Francois Bouzom; Jun Chen; Yuan Chen; Yumi Cleary; Christiane Collins; Gemma L Dickinson; Nassim Djebli; Heidi J Einolf; Iain Gardner; Felix Huth; Faraz Kazmi; Feras Khalil; Jing Lin; Aleksandrs Odinecs; Chirag Patel; Haojing Rong; Edgar Schuck; Pradeep Sharma; Shu-Pei Wu; Yang Xu; Shinji Yamazaki; Kenta Yoshida; Malcolm Rowland
Journal:  Clin Pharmacol Ther       Date:  2018-02-02       Impact factor: 6.875

6.  Pregnancy-specific physiologically-based toxicokinetic models for bisphenol A and bisphenol S.

Authors:  Jeremy Gingrich; David Filipovic; Rory Conolly; Sudin Bhattacharya; Almudena Veiga-Lopez
Journal:  Environ Int       Date:  2020-12-22       Impact factor: 9.621

7.  A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP.

Authors:  Marival Bermejo; Bart Hens; Joseph Dickens; Deanna Mudie; Paulo Paixão; Yasuhiro Tsume; Kerby Shedden; Gordon L Amidon
Journal:  Pharmaceutics       Date:  2020-01-17       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.